KAIROS PHARMA LTD
KAPANYSE AMERICAN๐ #5168 by market capUS Equity
$0.45โผ $0.00 (โ0.87%)
Market closed ยท at closeTrack KAPA
Get earnings, price moves & breaking news on Telegram
24hโผ 0.9%
7dโผ 8.9%
14dโผ 8.4%
30dโผ 20.0%
ytdโผ 91.0%
1yโผ 90.5%
๐ฆMarket Cap
$2M
Small Cap
๐Revenue Growth (YoY)
โ
๐Gross Margin
โ
๐ตFCF Margin
โ
โ๏ธP/S Ratio
โ
Otter Score
โ
Insufficient data
Trading Snapshot
- Day Range
- $0.45 โ $0.45
- 52-Week Range
- $0.38 โ $7.28
- Volume (shares)
- 202
- Avg Volume (shares)
- โ
- Shares Outstanding
- 3.4M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- $-1.53
- Dividend Yield
- โ
KAIROS PHARMA LTD
KAPAFinancial Trends
Financial history unavailable.
About KAIROS PHARMA LTD
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
๐ฆฆ
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Overall Score
Insufficient data
โ/100
Analyst data unavailable.
Latest News & Updates
News unavailable.